Ovutrig
Ovutrig (High Purity Hcg) Warnings
In the case of female patients who want to be treated with Ovutrig (High Purity Hcg):
Since infertile female patients who undergo medically assisted reproduction (especially those who need in vitro fertilization), are known to often be suffering from tubal abnormalities, after a treatment with this drug they might experience much more ectopic pregnancies. This is why early ultrasound confirmation at the beginning of a pregnancy (to see whether the pregnancy is intrauterine or not) is crucial. – Pregnancies who have occurred after a treatment with this medicine are submitted to a higher risk of multiplets. – Female patients who have thrombosis, severe obesity or thrombophilia should not be prescribed this medicine as they have a higher risk of arterial or venous thromboembolic events after or during a treatment with Ovutrig (High Purity Hcg).
Female patients who have been treated with this medicine are usually more prone to pregnancy losses.
Female patients who have been treated with this medicine are usually more prone to pregnancy losses.
In the case of male patients: A prolonged treatment with Ovutrig (High Purity Hcg) is known to regularly lead to increased production of androgen. Therefore:
Patients who are suffering from overt or latent cardiac failure, hypertension, renal dysfunction, migraine or Epilepsy might not be allowed to start using this medicine or might have to be prescribed a lower dose of Ovutrig (High Purity Hcg). – This medicine should be used with extreme cautious in the case of prepubertal teenagers in order to reduce the risk of experiencing precocious sexual development or premature epiphyseal closure. This type of patients’ skeletal maturation should be closely and regularly monitored.
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon